Hiratani T, Yamaguchi H
Research Center for Medical Mycology, Teikyo University.
Jpn J Antibiot. 1994 Feb;47(2):125-8.
Using 9 strains of Candida albicans mutants resistant to either a triazole-antifungal vibunazole, an imidazole-antifungal ketoconazole or a morpholine-antifungal amorolfine, experiments were conducted to see whether cross-resistance was developed to any of these 3 different families, as well as to an allylamine-antifungal terbinafine. All four compounds are known to selectively inhibit fungal ergosterol biosynthesis. All the mutant strains were found to be more or less resistant to other families of ergosterol biosynthesis inhibitors but not to terbinafine.
使用9株对三唑类抗真菌药维布康唑、咪唑类抗真菌药酮康唑或吗啉类抗真菌药阿莫罗芬耐药的白色念珠菌突变株进行实验，以观察是否会对这3个不同类别的药物以及烯丙胺类抗真菌药特比萘芬产生交叉耐药性。已知这四种化合物均能选择性抑制真菌麦角甾醇的生物合成。结果发现，所有突变株或多或少都对其他类别的麦角甾醇生物合成抑制剂耐药，但对特比萘芬不耐药。
